Lord, Abbett & Co
ESPR icon

Lord, Abbett & Co’s Esperion Therapeutics ESPR Stock Holding History

Lord, Abbett & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-467,466
Closed -$2.91M – 581
2022
Q4 		$2.91M Buy
+467,466
New +$3.34M 0.01% 531
2018
Q2 		– Sell
-91,887
Closed -$6.65M – 860
2018
Q1 		$6.65M Sell
91,887
-138,565
-60% -$10.2M 0.02% 688
2017
Q4 		$15.2M Sell
230,452
-5,437
-2% -$293K 0.04% 537
2017
Q3 		$11.8M Buy
235,889
+96,912
+70% +$4.67M 0.03% 603
2017
Q2 		$6.43M Buy
+138,977
New +$5.11M 0.02% 730

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Lord, Abbett & Co's ESPR Position: Q1 2023 in Review

Lord, Abbett & Co sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 467,466 shares — an estimated $2.91M sold.

Lord, Abbett & Co first reported a position in ESPR in Q2 2017 and held it in 5 quarters. The position peaked at $15.2M in Q4 2017. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Lord, Abbett & Co reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 467,466 Esperion Therapeutics shares in Q1 2023, an estimated $2.91M.
  • Lord, Abbett & Co first reported a position in Esperion Therapeutics in Q2 2017 and held it in 5 quarters.
  • Lord, Abbett & Co's Esperion Therapeutics position peaked at $15.2M in Q4 2017.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Lord, Abbett & Co's 13F filing for Q1 2023, filed 12 May 2023.